Compare HCA Health Inc (HCA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Sana Biotechnology Inc — how do they compare? HCA Health Inc trades at $411.81 (market cap $89.08B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: HCA Health Inc is far larger — about 78.8× Sana Biotechnology Inc's market cap, and HCA Health Inc pays a 0.76% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HCA | SANA | |
|---|---|---|
Market Cap | $89.08B | $1.13B |
Sector | Health | Health |
52-Week High | $545.13 | $5.92 |
52-Week Low | $361.32 | $2.68 |
Enterprise Value | $139.62B | $1.05B |
Dividend Yield | 0.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.66, up 0.15% today, with a bullish technical signal from moving averages and a P/E of 13.8. Revenue grew to $75.60B in 2025, with net income of $6.78B, and the company has beaten EPS estimates for three consecutive quarters. Recent corporate actions include a $0.78 dividend scheduled for September 2026.
The outlook is positive with a consensus price target of $449.93, implying 8.5% upside, supported by strong earnings and institutional buy ratings. Risks include high debt levels, regulatory investigations, and expense pressures noted in Q2 2026 results. Investors should weigh solid fundamentals against legal and operational headwinds.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
